A consortium of 7 European partners has undertaken the challenging task to develop a microfluidic system (μTAS) capable of the isolation/enrichment and consecutive RNA/DNA characterization of circulating tumor cells (CTCs), to be used as a minimally-invasive tool for the early, primary diagnosis of cancer, for cancer therapy monitoring and for the detection of recurrent disease. The lab-on-chip device will integrate three microsystem modules with state-of-the-art microfluidics/microengineering: 1) magneto-electronics based device for the isolation, enrichment and detection of rare cells from complex samples; based on immunomagnetic isolation; 2) multiplexed, micro-scale RNA/DNA amplification on the isolated rare cells, based on Multiplexed Ligand Probe Amplification (MLPA); 3) array of electrochemical biosensors for the consecutive analysis of amplified nucleic acids.
Journal: TechConnect Briefs
Volume: 2, Technical Proceedings of the 2007 NSTI Nanotechnology Conference and Trade Show, Volume 2
Published: May 20, 2007
Pages: 229 - 231
Industry sector: Medical & Biotech
Topics: Diagnostics & Bioimaging